SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Edward W. Richmond who wrote (221)9/16/1997 11:21:00 PM
From: Paul S.   of 1185
 
Looking at all the facts surrounding Nortran, and following the biotechs in general, you have to take into consideration the following. That NRT is past phase one developments on its RSD921. The company has 22 million shares out, trading at $2.00 that is still only 45 million in market cap. Neil Maedel(the Protrader) says that the multiples for biotechs in general, that are at the stage of Nortran should have a market cap of about 90 million. That would be $4.00 per share. This is probably where Roman Franco gets his figure from. Bottom line here is that NRT is trading great volume and I think for the first time this year I will average up and add to my position. I for one think they might be right or at least we will be able to see $3.00 in the near future.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News